From recurrent flank pain to systemic oxalosis: a case of primary hyperoxaluria type 1 requiring dual organ transplantation
Open Access
- 7 May 2026
- journal article
- case report
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3753-3758
Abstract
Introduction and importance: Primary hyperoxalurias (PH) are rare autosomal recessive inherited disorders that disrupt the metabolism of glyoxylate and oxalate. The most common type, primary hyperoxaluria type 1 (PH1), is caused by a deficiency in the liver enzyme alanine-glyoxylate aminotransferase (AGT), leading to the overproduction and excessive urinary excretion of oxalate. Case presentation: On routine evaluation, the patient presented with deranged renal function and echogenic kidneys. Imaging via KUB X-ray revealed radio-opaque kidney stones, small shrunken kidneys, and nephrocalcinosis, indicating progression to end-stage kidney disease (ESKD). Additional systemic manifestations included increased lumbar bone density and pulmonary fibrosis. Diagnosis was definitively confirmed through elevated 24-hour urinary oxalate levels and genetic screening showing an AGXT gene mutation. This necessitated combined liver–kidney transplantation (CLKT): the liver graft provides the missing AGT enzyme to stop oxalate production, while the kidney graft replaces damaged organs and discontinues chronic dialysis. Clinical discussion: PH1 must be suspected in pediatric patients presenting with recurrent urolithiasis or nephrocalcinosis, especially in clinical cases of consanguinity. Early interventions – high fluid intake, crystallization inhibitors, and pyridoxine – can help preserve kidney function. For patients reaching ESKD, combined transplantation is the most effective approach to correct the underlying metabolic error and stop oxalate accumulation. Conclusion: This case highlights the diagnostic challenge of PH1, where the initial presentation with flank pain and urinary symptoms may mimic a urinary tract infection, placing the patient at potential risk of urosepsis if misdiagnosed or untreated. CLKT remains the definitive treatment in advanced disease.Keywords
This publication has 24 references indexed in Scilit:
- Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young childrenGenetics in Medicine, 2022
- Primary hyperoxaluria type 1: update and additional mutation analysis of theAGXTgeneHuman Mutation, 2009
- [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluriaKidney International, 2008
- The Primary HyperoxaluriasSeminars in Nephrology, 2008
- Model for end-stage liver disease (MELD) exception for primary hyperoxaluriaLiver Transplantation, 2006
- AASLD practice guidelinesHepatology, 2005
- Transplantation for primary hyperoxaluria in the United StatesKidney International, 1999
- Management of primary hyperoxaluria: efficacy of oral citrate administrationPediatric Nephrology, 1993
- The effect of Pyridoxine on Oxalate Dynamics in three Cases of Primary Hyperoxaluria (with Glycollic Aciduria)Clinical Science, 1985
- The Action of Pyridoxine in Primary HyperoxaluriaClinical Science, 1970